Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])-Reference-Cited by-同舟云学术

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

Published:2016-05 Issue:5 Volume:74 Page:851-861.e4
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Strober Bruce E.,Bissonnette Robert^ORCID,Fiorentino David,Kimball Alexa B.,Naldi Luigi,Shear Neil H.,Goyal Kavitha^ORCID,Fakharzadeh Steven,Calabro Stephen,Langholff Wayne,You Yin,Galindo Claudia,Lee Seina,Lebwohl Mark G.

Publisher

Elsevier BV

Subject

Dermatology

Reference37 articles.

1. On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis;Puig;J Clin Pharm Ther,2015

2. Comparative-effectiveness research–implications of the Federal Coordinating Council's report;Conway;N Engl J Med,2009

3. Prioritizing comparative-effectiveness research–IOM recommendations;Iglehart;N Engl J Med,2009

4. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis;Abuabara;J Am Acad Dermatol,2013

5. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial;Krueger;Br J Dermatol,2005

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency of use and annual costs of biological therapy for psoriasis in Colombia in 2019;International Journal of Dermatology;2024-07-19

2. Impact of residual skin lesions and previous biologic treatment failure on patient‐reported outcomes in patients with psoriasis receiving biologic treatment;The Journal of Dermatology;2024-04-25

3. Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia;Cost Effectiveness and Resource Allocation;2023-12-09

4. Clinical and patient‐reported outcomes from the first 4 years of a Psoriasis Biologics Registry in Singapore;Experimental Dermatology;2023-08-16

5. Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR);Journal of Cutaneous Medicine and Surgery;2023-08-11